Compare AbCellera Biologics Inc (ABCL) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs L3Harris Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while L3Harris Technologies Inc trades at $291.88 (market cap $55.03B). The key difference: L3Harris Technologies Inc is far larger — about 23.4× AbCellera Biologics Inc's market cap, and L3Harris Technologies Inc pays a 1.69% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LHX | |
|---|---|---|
Market Cap | $2.35B | $55.03B |
Sector | Health | Industrials |
52-Week High | $8.12 | $378.48 |
52-Week Low | $2.78 | $257.09 |
Enterprise Value | $1.99B | $65.80B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
LHX trades at $295.4, down 2.21% today, with a bullish technical signal despite near-term overbought RSI conditions. The company reported strong Q1 2026 earnings, beating estimates with $5.7B revenue and a 1.4x book-to-bill ratio, boosting its backlog to a record $40.7B. Recent news highlights expansion in missile production and new defense contracts, supporting growth momentum.
LHX presents a favorable outlook with robust defense sector tailwinds and consistent earnings beats, though elevated valuation metrics and geopolitical risks warrant caution. Analyst consensus is strongly bullish with a $367.50 price target, implying significant upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
